In Australian indigenous children, what is the effect of oral nitazoxanide versus placebo on acute gastroenteritis?

Telethon Kids Institute0 个研究点目标入组 216 人开始时间: 2014年4月9日最近更新: 2024年2月27日

适应症

试验速览

暂无简介。

•1. Infant /child between =>3 months and <5 years of age
•2. Infant/ child identified as Indigenous by the legally responsible care-giver
•3. Infant /child has been/will be admitted to hospital for acute infectious gastroenteritis (in the opinion of the admitted doctor and/or study doctor/nurse )
•4. The legally responsible care-giver is willing for their infant/ child to participate in the study and who would be expected to comply with the requirements of the protocol, including being able and willing to be contacted by telephone after discharge where necessary
•5. The legally responsible care-giver is willing to allow other parties involved in the treatment of his or her child (including the general practitioner, paediatrician, hospital medical and nursing staff, community clinic staff) to be notified of participation in the trial
•6. The legally responsible care-giver is willing to allow to allow the study team to obtain a vaccination history from Australian Childhood Immunisation Register (ACIR) and/or local provider
•7. The legally responsible care-giver is willing to allow the study team to obtain an interim medical history from the participant’s electronic medical records and/or from the participant’s general practitioner for the period from enrolment to study day 60
•8. Informed consent for the infant’s/child’s participation in the study has been given by the legally responsible care-giver

•1. Admitted for =>48 hours at the point of enrolment
•2. Duration of symptoms of greater than 14 days without apparent worsening of symptoms consistent with an acute pathology
•3. Presence of grossly bloody diarrhoea
•4. Clinical suspicion of non-infectious cause (e.g. diagnosed with a pre-existing medical condition predisposing to non-infectious diarrhoea, for example inflammatory bowel disease) except for environmental enteropathy)
•5. Contraindication to the study drug or placebo (e.g. allergy)
•6. Diagnosis of infection with an enteric pathogen where anti-microbial treatment with an alternative antimicrobial is the standard of care (e.g. Shigella sp.)
•7. Inability to tolerate either the oral or nasogastric route (e.g. ileus)
•8. Clinical suspicion of intestinal obstruction including bilious vomiting
•9. Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
•10. Receipt of more than 2 weeks of immuno-suppressants or immune modifying drugs, (e.g. prednisolone >0.5 mg/kg/day)
•11. Receipt of investigational drug/vaccine, other than the drugs used in the study, within 30 days prior to receiving the first dose of NTZ or their planned use during the study period, until 1 month after the administration of the final dose of NTZ
•12. Previously enrolled in the trial

发起方